Abstract:Background: Recepteur d'origine nantais (RON) is a receptor tyrosine kinase that is activated by a serum-derived, macrophage stimulating protein (MSP) growth factor and is expressed in many malignant tumors. The aim of the present study was to reveal the protein expression profile of RON and its relationship with clinicopathological characteristics of gastric carcinoma and prognosis.Methods: Gastric carcinoma tissue from 98 patients, along with 29 specimens of paraneoplastic tissue and 10 specimens of normal gastric mucosa, were examined by immunohistochemistry (IHC). Western blot analysis of 19 samples of gastric carcinoma tissue and corresponding paraneoplastic tissue, 8 specimens of normal gastric mucosa, and 2 specimens of normal lymph node samples also detected expression of a splice variant of RON, RON Delta 165. All samples obtained were accompanied by patient follow-up data that ranged from 3 to 89 months (median time: 22 months).Results: The rate of positive RON expression differed significantly between gastric carcinoma tissues [56.1%, (55/98)] and paraneoplastic tissues [25.6%, (8/29)] (p = 0.007). In contrast, RON expression was absent in normal gastric mucosa samples. RON expression positively correlated with the invasive depth of the tumor (p = 0.019), perigastric lymph nodes metastasis (p = 0.019), and TNM stage (p = 0.001). However, RON expression was independent of tumor growth pattern according to Bormann criteria (p = 0.209), histopathological grade (p = 0.196), and incidence of distant metastasis (p = 0.400). RON expression was not related to a patient's survival rate (p = 0.195). RON Delta 165 was strongly expressed in fresh gastric carcinoma tissue, corresponding paraneoplastic tissue, and perigastric lymph nodes with metastatic carcinoma. In contrast, expression of RON Delta 165 was not observed in normal gastric mucosa and normal lymph node tissue samples.Conclusion: RON expression is significant in gastric carcinoma tissue and corresponding paraneoplastic tissue, but is not expressed in normal gastric mucosa. Expression of RON Delta 165 was similarly observed in gastric carcinoma tissue and in metastases present in lymph node tissues. We hypothesize that RON and its splice variant play an important role in the occurrence, progression, and metastasis of gastric carcinoma, and therefore may represent a useful marker to evaluate the biological activity of gastric carcinoma.

Overexpression and Activation of the RON Receptor Tyrosine Kinase in a Panel of Human Colorectal Carcinoma Cell Lines.

Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential

Colorectal Cancer Progression is Marked by Overexpression and Activation of Splicing Variants of the Ron Receptor Tyrosine Kinase

Effects of Heterogously- Expressed RON Receptor Tyrosine Kinase on Motile/invasive Ability of Human Colorectal Cancer Cell Line RKO

Expression of the RON Receptor Tyrosine Kinase and Its Association with Gastric Carcinoma Versus Normal Gastric Tissues.

A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.

Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo

Blocking Tumorigenic Activities of Colorectal Cancer Cells by a Splicing RON Receptor Variant Defective in the Tyrosine Kinase Domain

Expression of Receptor Tyrosine Kinase RON in Renal Tumors

Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.

Alterations in a Defined Extracellular Region of the RON Receptor Tyrosine Kinase Promote RON-mediated Motile and Invasive Phenotypes in Epithelial Cells.

Oncogenesis of RON Receptor Tyrosine Kinase： a Molecular Target for Malignant Epithelial Cancers

Receptor tyrosine kinase RON and tumor

Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.

β-Arrestin-1-dependent activation of extracellular signal-regulated kinases in RON receptor-mediated tumorigenic activities in colon cancer cells

RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells

Deletion or Insertion in the First Immunoglobulin-Plexin-Transcription (ipt) Domain Differentially Regulates Expression and Tumorigenic Activities of Ron Receptor Tyrosine Kinase

RON Mediates Tumor-Promoting Effects in Endometrial Adenocarcinoma

Multiple Pulmonary Adenomas in the Lung of Transgenic Mice Overexpressing the RON Receptor Tyrosine Kinase

Pathogenesis Of Ron Receptor Tyrosine Kinase In Cancer Cells: Activation Mechanism, Functional Crosstalk, And Signaling Addiction

Inhibition of MSP-RON Signaling Pathway in Cancer Cells by a Novel Soluble Form of RON Comprising the Entire Sema Sequence.